{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T21:21:36Z","timestamp":1789161696523,"version":"build-2803163510"},"reference-count":31,"publisher":"American Society of Hematology","issue":"3","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,2,11]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>The International Consensus (ICC) and World Health Organization fifth edition (WHO5) classifications introduced new, but differing, categories of myeloid disease defined by TP53 mutations. We reviewed a cohort of 188 cases of TP53-mutated myeloid disease to determine how diagnoses and outcomes differ between the 2 classifications. Overall, 120 (64%) cases were classified differently by the ICC and WHO5, including 24 of 80 (30%) cases with &amp;lt;20% blasts. These cases were discrepantly categorized primarily because of inclusion of complex karyotype (CK) as a surrogate for biallelic TP53 inactivation only in the ICC. However, there were no significant differences in clinicopathologic characteristics or overall survival between cases categorized as TP53-mutated disease by both classifications and those with a single TP53 mutation and CK, suggesting that CK reliably identifies TP53-mutated cases with biallelic TP53 inactivation. Most cases of acute myeloid leukemia (AML; 96\/102 [94%]) were discrepantly diagnosed between the ICC and WHO5 because of the introduction of AML with mutated TP53 as a distinct category only in the ICC. Nearly all of these were instead diagnosed as AML, myelodysplasia related (AML-MR) by WHO5. However, when compared with a separate cohort of patients with AML-MR without TP53 mutations, patients with TP53-mutated AML showed a distinct genetic profile and significantly worse overall survival, supporting the inclusion of AML with mutated TP53 as a distinct disease category. Overall, our results show that a significant percentage of TP53-mutated myeloid disease is classified differently by the ICC and WHO5 and highlight areas to address in future classification systems.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2024014140","type":"journal-article","created":{"date-parts":[[2024,11,13]],"date-time":"2024-11-13T21:01:52Z","timestamp":1731531712000},"page":"445-454","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":18,"title":["Diagnosis of <i>TP53<\/i>-mutated myeloid disease by the ICC and WHO fifth edition classifications"],"prefix":"10.1182","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8502-5834","authenticated-orcid":false,"given":"Stephanie A.","family":"Hart","sequence":"first","affiliation":[{"name":"Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4501-7768","authenticated-orcid":false,"given":"Laura A.","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2832-2039","authenticated-orcid":false,"given":"Adam C.","family":"Seegmiller","sequence":"additional","affiliation":[{"name":"Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9173-1401","authenticated-orcid":false,"given":"Emily F.","family":"Mason","sequence":"additional","affiliation":[{"name":"Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2025,1,29]]},"reference":[{"issue":"6","key":"2025032119364023200_bib1","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/j.cell.2017.08.028","article-title":"Putting p53 in context","volume":"170","author":"Kastenhuber","year":"2017","journal-title":"Cell"},{"issue":"22","key":"2025032119364023200_bib2","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1056\/NEJMoa1301689","article-title":"Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia","volume":"368","author":"Cancer Genome Atlas Research Network","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"2025032119364023200_bib3","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1182\/blood-2016-01-693879","article-title":"Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia","volume":"128","author":"Metzeler","year":"2016","journal-title":"Blood"},{"issue":"3","key":"2025032119364023200_bib4","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1038\/leu.2015.304","article-title":"Impact of TP53 mutation variant allele frequency on phenotype and outcomes in myelodysplastic syndromes","volume":"30","author":"Sallman","year":"2016","journal-title":"Leukemia"},{"issue":"3","key":"2025032119364023200_bib5","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1182\/bloodadvances.2019001101","article-title":"Genomic context and TP53 allele frequency define clinical outcomes in TP53-mutated myelodysplastic syndromes","volume":"4","author":"Montalban-Bravo","year":"2020","journal-title":"Blood Adv"},{"issue":"15","key":"2025032119364023200_bib6","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1200\/JCO.2010.31.8576","article-title":"TP53 mutations in low-risk myelodysplastic syndromes with del(5q) predict disease progression","volume":"29","author":"Jadersten","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"issue":"9","key":"2025032119364023200_bib7","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1056\/NEJMc1608739","article-title":"Genomic classification in acute myeloid leukemia","volume":"375","author":"Lemonnier","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"7540","key":"2025032119364023200_bib8","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/nature13968","article-title":"Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia","volume":"518","author":"Wong","year":"2015","journal-title":"Nature"},{"issue":"24","key":"2025032119364023200_bib9","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1182\/blood.2020006158","article-title":"TP53 mutations in myelodysplastic syndromes and secondary AML confer an immunosuppressive phenotype","volume":"136","author":"Sallman","year":"2020","journal-title":"Blood"},{"issue":"12","key":"2025032119364023200_bib10","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"Dohner","year":"2022","journal-title":"Blood"},{"issue":"9","key":"2025032119364023200_bib11","doi-asserted-by":"crossref","first-page":"2847","DOI":"10.1182\/bloodadvances.2021006239","article-title":"TP53 mutation defines a unique subgroup within complex karyotype de novo and therapy-related MDS\/AML","volume":"6","author":"Weinberg","year":"2022","journal-title":"Blood Adv"},{"issue":"6","key":"2025032119364023200_bib12","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1056\/NEJMoa1611604","article-title":"Prognostic mutations in myelodysplastic syndrome after stem-cell transplantation","volume":"376","author":"Lindsley","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"17","key":"2025032119364023200_bib13","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1182\/blood-2016-12-754796","article-title":"Genetic abnormalities in myelodysplasia and secondary acute myeloid leukemia: impact on outcome of stem cell transplantation","volume":"129","author":"Yoshizato","year":"2017","journal-title":"Blood"},{"issue":"10","key":"2025032119364023200_bib14","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1038\/s41591-020-1008-z","article-title":"Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes","volume":"26","author":"Bernard","year":"2020","journal-title":"Nat Med"},{"issue":"15","key":"2025032119364023200_bib15","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1182\/blood.2021014472","article-title":"Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome","volume":"139","author":"Grob","year":"2022","journal-title":"Blood"},{"issue":"26","key":"2025032119364023200_bib16","doi-asserted-by":"crossref","first-page":"2989","DOI":"10.1182\/blood-2018-02-832360","article-title":"Prognostic factors influencing survival after allogeneic transplantation for AML\/MDS patients with TP53 mutations","volume":"131","author":"Ciurea","year":"2018","journal-title":"Blood"},{"issue":"1","key":"2025032119364023200_bib17","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1182\/blood.2021013983","article-title":"TP53 copy number and protein expression inform mutation status across risk categories in acute myeloid leukemia","volume":"140","author":"Tashakori","year":"2022","journal-title":"Blood"},{"issue":"7","key":"2025032119364023200_bib18","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1038\/s41375-018-0351-2","article-title":"TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups","volume":"33","author":"Haase","year":"2019","journal-title":"Leukemia"},{"issue":"4","key":"2025032119364023200_bib19","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.beha.2018.09.010","article-title":"Patterns of mutations in TP53 mutated AML","volume":"31","author":"Welch","year":"2018","journal-title":"Best Pract Res Clin Haematol"},{"key":"2025032119364023200_bib20","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s13045-015-0139-z","article-title":"TP53 mutation characteristics in therapy-related myelodysplastic syndromes and acute myeloid leukemia is similar to de novo diseases","volume":"8","author":"Ok","year":"2015","journal-title":"J\u00a0Hematol Oncol"},{"issue":"9","key":"2025032119364023200_bib21","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1182\/blood-2011-08-375758","article-title":"TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome","volume":"119","author":"Rucker","year":"2012","journal-title":"Blood"},{"issue":"22","key":"2025032119364023200_bib22","doi-asserted-by":"crossref","first-page":"5681","DOI":"10.1182\/bloodadvances.2020003120","article-title":"Prognostic and therapeutic impacts of mutant TP53 variant allelic frequency in newly diagnosed acute myeloid leukemia","volume":"4","author":"Short","year":"2020","journal-title":"Blood Adv"},{"issue":"8","key":"2025032119364023200_bib23","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1038\/leu.2016.74","article-title":"High prevalence and allele burden-independent prognostic importance of p53 mutations in an inner-city MDS\/AML cohort","volume":"30","author":"Goel","year":"2016","journal-title":"Leukemia"},{"issue":"11","key":"2025032119364023200_bib24","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International Consensus Classification of myeloid neoplasms and acute leukemia: integrating morphological, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"key":"2025032119364023200_bib25","author":"World Health Organization","year":"2024"},{"issue":"9","key":"2025032119364023200_bib26","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/S1470-2045(15)00201-6","article-title":"Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study","volume":"16","author":"Ravandi","year":"2015","journal-title":"Lancet Oncol"},{"issue":"suppl_1","key":"2025032119364023200_bib27","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1182\/blood-2019-131520","article-title":"The VITAL trial: phase II trial of vosaroxin and infusional cytarabine for frontline treatment of acute myeloid leukemia","volume":"134","author":"Strickland","year":"2019","journal-title":"Blood"},{"issue":"29","key":"2025032119364023200_bib28","doi-asserted-by":"crossref","first-page":"4791","DOI":"10.1200\/JCO.2008.16.0259","article-title":"Monosomal karyotype in acute myeloid leukemia: a better indicator of poor prognosis than a complex karyotype","volume":"26","author":"Breems","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"issue":"269","key":"2025032119364023200_bib30","doi-asserted-by":"crossref","first-page":"pl1","DOI":"10.1126\/scisignal.2004088","article-title":"Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal","volume":"6","author":"Gao","year":"2013","journal-title":"Sci Signal"},{"issue":"5","key":"2025032119364023200_bib31","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","article-title":"The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data","volume":"2","author":"Cerami","year":"2012","journal-title":"Cancer Discov"},{"issue":"6","key":"2025032119364023200_bib29","doi-asserted-by":"crossref","first-page":"390.e1","DOI":"10.1016\/j.jtct.2023.03.008","article-title":"TP53 mutations are associated with increased infections and reduced hematopoietic cell transplantation rates in myelodysplastic syndrome and acute myeloid leukemia","volume":"29","author":"Marvin-Peek","year":"2023","journal-title":"Transplant Cell Ther"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/3\/445\/2353398\/blooda_adv-2024-014140-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/3\/445\/2353398\/blooda_adv-2024-014140-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,21]],"date-time":"2025-03-21T19:48:35Z","timestamp":1742586515000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/9\/3\/445\/525977\/Diagnosis-of-TP53-mutated-myeloid-disease-by-the"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,29]]},"references-count":31,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,2,11]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2024014140","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,29]]}}}